BARCELONA, Spain — Efgartigimod could have a role to play in the treatment of both myositis and Sjögren disease, according to data from two “proof-of-concept” phase 2 studies reported at the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback